肺纤方提取物干预肺纤维化模型大鼠肺微血管内皮细胞新生血管形成的体外研究

Intervention of Feixian Formula extract on pulmonary microvascular endothelial cell migration and angiogenesis in vitro in rat model of pulmonary fibrosis

目的探讨肺纤方提取物体外干预肺纤维化微血管生成的作用及机制。方法从肺纤维化模型大鼠分离培养肺微血管内皮细胞,将其等量分为空白组、氯沙坦组、泼尼松组、肺纤方大剂量组、肺纤方中剂量组、肺纤方小剂量组。对各组的迁移细胞及微血管内皮细胞形成的血管进行计数。结果与空白组和泼尼松组相比,肺纤方大、中剂量、氯沙坦均能抑制内皮细胞的迁移(P<0.05)。氯沙坦、肺纤方各剂量均能抑制血管形成(P<0.05),其中肺纤方大剂量几乎完全抑制血管形成。结论肺纤方具有抑制肺纤维化大鼠体外培养的肺微血管内皮细胞的迁移及新生血管形成,从而发挥抗肺纤维化作用。

Objective To probe into the mechanism of Feixian Formula （FXF）, a Chinese herbal compound, in prevention pulmonary mierovaseular endothelial cells （PMVECs） migration and angiogenesis in vitro. Methods PMVECs isolated from rat model of pulmonary fibrosis （PF） were cultured and divided into blank group, losartan group, prednisone group, low-, mid-, and high-dose of FXF groups. Migrating cells and new vessels in each group were counted. Results High-dose and mid-dose of FXF and losartan inhibited PMVECs migration significantly （P 〈 0. 05 ）. High-dose, mid-dose, low-dose of FXF and losartan inhibited formation of new vessels, even high-dose of FXF completely inhibited blood vessel formation. Conclusion The potential mechanism of anti-pulmonary fibrosis of FXF in vitro is related to inhabitation of PMVECs migration and new vessels formation.